Orthopedic Consolidation Continues: IsoTis Deal Unites Bone Graft Developers
This article was originally published in The Gray Sheet
Executive Summary
IsoTis will continue to develop its Allox allogenic growth factor spray for chronic wound treatment, while directing the majority of its R&D at osteobiologics